Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 68 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age less than physiologic 68 years.
Patients with NHL and HL with an indication for allogeneic transplantation as follows:
Aggressive lymphoma and Hodgkin lymphoma; relapse after autologous transplants
Follicular lymphoma; failure of at least one prior regimen
Disease must be at chemo-sensitive or stable status to prior therapy before transplant.
Patients must have an HLA matched related or unrelated donor willing to donate either peripheral blood stem cells or bone marrow. Matching is based on high-resolution class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) typing. The goal is to transplant > 3 x 106 CD34+ cells per kg body weight of the recipient
Patients must sign written informed consent
Adequate birth control in fertile patients
Overt progressive disease prior to transplantation.
Bilirubin > 3.0 mg/dl, transaminases > 3 times upper normal limit